Eli Lilly obesity pill disappoints in trial, sending shares down 14%
's potential
obesity
pill helped patients lose less weight than investors had hoped during a trial, sending shares in the
drugmaker
down more than 14 per cent in early trading.
The pharmaceutical group said on Thursday that patients taking orforglipron lost an average of 12.4 per cent of their body weight, at the lower end of the market's expectations for the closely watched medicine. Trial participants taking a placebo lost 0.9 per cent.
A pill is expected to offer less dramatic weight loss than injectables, where Lilly's
Zepbound
currently offers the most weight loss at an average of 23 per cent.
Evan Seigerman, an analyst at BMO Capital markets, said investors had been hoping for a minimum weight loss of about 13.7 per cent of body weight.
Novo Nordisk
's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15 per cent of their body weight. Shares in Novo Nordisk, Lilly's main rival in the obesity market, jumped as much as 14 per cent.
Mr Seigerman also said the trial showed the rate of side effects when taking Lilly's pill – nausea, vomiting and diarrhoea – was slightly worse than expected.
The trial result was announced as Lilly reported its second-quarter results, beating analysts' expectations, and raised the midpoint of its guidance for the full year. David Ricks, Lilly's chief executive, said it was 'another quarter of strong performance'.
The pharmaceutical industry is under pressure from the Trump administration to lower prices voluntarily, or face a 'Most Favoured Nation' drug pricing policy that would peg US drug prices to the lower prices in other developed nations.
Mr Ricks warned against importing 'foreign pricing controls', arguing it would harm patients and US competitiveness.
The company reported revenues of $15.6 billion (€13.4 billion) in the three months to June, up 38 per cent on the same period last year. Sales of Zepbound, prescribed for obesity, soared by 172 per cent, and Mounjaro, prescribed for diabetes, jumped 68 per cent.
Lilly now expects full-year revenue between $60 billion to $62 billion, up from its previous range of $58 billion to $61 billion.
The optimistic outlook contrasts sharply with rival Novo Nordisk, which lowered its forecasts for profit and sales growth last week, wiping €60 billion off its value. Novo Nordisk has been losing ground to Lilly in the US market, as well as facing competition from copycat versions of its weight loss and diabetes drugs.
Investors had been excited that Lilly could dominate the market for oral weight loss drugs with orforglipron.
While the trial result disappointed investors, the once-daily pill met the trial's goals, including showing it can have a positive impact on heart health, and Lilly said it was on track to submit the medicine to regulators for approval later this year.
Just over 10 per cent of the high-dose patients dropped out of the Lilly trial due to adverse side effects, the company said. No liver safety issues were seen.
In April, Lilly shares jumped almost 15 per cent when another trial, among diabetic patients, showed it could help them lose weight and lower their blood sugar.
Daniel Skovronsky, Lilly's chief scientific officer, told analysts they should be wary of comparing trials over different time periods and in different populations.
'Wall Street is kind of focused on the exact numbers here, the cross trial comparisons, [but] I don't think that carries over to the real world,' he said. – Copyright The Financial Times Limited 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
20 hours ago
- Irish Times
Eli Lilly obesity pill disappoints in trial, sending shares down 14%
Eli Lilly 's potential obesity pill helped patients lose less weight than investors had hoped during a trial, sending shares in the drugmaker down more than 14 per cent in early trading. The pharmaceutical group said on Thursday that patients taking orforglipron lost an average of 12.4 per cent of their body weight, at the lower end of the market's expectations for the closely watched medicine. Trial participants taking a placebo lost 0.9 per cent. A pill is expected to offer less dramatic weight loss than injectables, where Lilly's Zepbound currently offers the most weight loss at an average of 23 per cent. Evan Seigerman, an analyst at BMO Capital markets, said investors had been hoping for a minimum weight loss of about 13.7 per cent of body weight. Novo Nordisk 's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15 per cent of their body weight. Shares in Novo Nordisk, Lilly's main rival in the obesity market, jumped as much as 14 per cent. Mr Seigerman also said the trial showed the rate of side effects when taking Lilly's pill – nausea, vomiting and diarrhoea – was slightly worse than expected. The trial result was announced as Lilly reported its second-quarter results, beating analysts' expectations, and raised the midpoint of its guidance for the full year. David Ricks, Lilly's chief executive, said it was 'another quarter of strong performance'. The pharmaceutical industry is under pressure from the Trump administration to lower prices voluntarily, or face a 'Most Favoured Nation' drug pricing policy that would peg US drug prices to the lower prices in other developed nations. Mr Ricks warned against importing 'foreign pricing controls', arguing it would harm patients and US competitiveness. The company reported revenues of $15.6 billion (€13.4 billion) in the three months to June, up 38 per cent on the same period last year. Sales of Zepbound, prescribed for obesity, soared by 172 per cent, and Mounjaro, prescribed for diabetes, jumped 68 per cent. Lilly now expects full-year revenue between $60 billion to $62 billion, up from its previous range of $58 billion to $61 billion. The optimistic outlook contrasts sharply with rival Novo Nordisk, which lowered its forecasts for profit and sales growth last week, wiping €60 billion off its value. Novo Nordisk has been losing ground to Lilly in the US market, as well as facing competition from copycat versions of its weight loss and diabetes drugs. Investors had been excited that Lilly could dominate the market for oral weight loss drugs with orforglipron. While the trial result disappointed investors, the once-daily pill met the trial's goals, including showing it can have a positive impact on heart health, and Lilly said it was on track to submit the medicine to regulators for approval later this year. Just over 10 per cent of the high-dose patients dropped out of the Lilly trial due to adverse side effects, the company said. No liver safety issues were seen. In April, Lilly shares jumped almost 15 per cent when another trial, among diabetic patients, showed it could help them lose weight and lower their blood sugar. Daniel Skovronsky, Lilly's chief scientific officer, told analysts they should be wary of comparing trials over different time periods and in different populations. 'Wall Street is kind of focused on the exact numbers here, the cross trial comparisons, [but] I don't think that carries over to the real world,' he said. – Copyright The Financial Times Limited 2025
Irish Examiner
21 hours ago
- Irish Examiner
Eli Lilly shares drop after weight-loss 'wonder drug' disappoints
Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company's current obesity medicine, which helped drive it to raise its yearly profit and sales outlook. Lilly's results from an obesity pill study, a drug key to unlocking billions of dollars of growth, didn't perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting, side-effects associated with so-called GLP-1 drugs. The data was a boon for rival Novo Nordisk. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Novo rose as much as 14.3% in Copenhagen, the most in almost four months. Drugmakers are in a hotly contested race to dominate the market for obesity medications. Lilly had moved into pole position against Novo thanks to Zepbound, its powerful injectable drug, but Lilly's sky-high valuation is tied in part to eventually turning its weight-loss pill into a blockbuster. Eli Lilly has major operations in Ireland with facilities in Kinsale, Little Island and Limerick. Investors say pills are a vital part of reaching more patients in the market that's expected to grow to $95bn (€82.2bn) by 2030. But the science has proved to be a challenge. Pfizer and AstraZeneca are among a handful of companies that have faced setbacks as they race to develop potent pills of their own. In Lilly's pill study, patients on the highest dose shed roughly 11% of their body weight, or 25 pounds, the company said. In late-stage trials, patients on Novo's injectable Wegovy lost about 15% of their weight over a 68-week period. The most common side-effects were nausea, vomiting and diarrhoea, which occurred at rates similar to existing GLP-1 drugs, Lilly said in a statement detailing the results. Notably, the medication didn't cause liver issues, a concern with other weight-loss pills in development. About 10% of patients dropped out of the study due to side-effects. Competition Lilly's data raises doubts over whether the pill, called orforglipron, can meet Wall Street's estimates of $12bn (€10.4bn) in annual sales by 2030, Bloomberg Intelligence analysts John Murphy and Christos Nikoletopoulos wrote. The company plans to submit the findings from the 18-month study involving more than 3,100 adults to regulatory agencies for approval by the end of the year. Detailed results will be presented at a medical conference in September. If approved, Lilly's once-daily pill would likely hit pharmacy shelves next year. Orforglipron is easier to manufacture than its current injectable Zepbound and is expected to be a cheaper option for patients. Novo has filed an oral version of its weight-loss blockbuster Wegovy for US approval, but it's more complicated to produce than Lilly's and will likely have more dosing restrictions, such as when patients can eat and drink. For investors, it has been a further example of Novo slipping behind after its next-generation obesity drug, CagriSema, also fell short of expectations in clinical trials. But Lilly's result offered Novo a welcome narrative shift on the same day that Maziar Mike Doustdar takes over as CEO from Lars Fruergaard Jorgensen. Eli Lilly sales forecast On Thursday, Lilly also increased its sales projections for the year and now expects revenue between $60 billion and $62 billion, up from a range of $58 billion to $61 billion. The company said in a statement it expects 2025 profit to reach $21.75 to $23 a share, up from $20.78 to $22.28. Lilly's second-quarter sales were $15.6 billion, beating analysts' average estimates of $14.7 billion. Zepbound surpassed expectations, while the diabetes medicine Mounjaro beat the Street's view. Adjusted profits were $6.29 per share, which outpaced analysts' $5.57 per share expectation.
Irish Times
a day ago
- Irish Times
Donald Trump calls on new Intel chief to resign
Donald Trump has called for the newly appointed chief executive of Intel , Lip-Bu Tan, to resign, alleging that the semiconductor industry veteran is 'highly conflicted'. 'The CEO of INTEL is highly CONFLICTED and must resign, immediately,' Trump said in his post on his Truth Social website on Thursday. 'There is no other solution to this problem.' The US president's post did not provide details of Tan's alleged conflicts of interest. Trump's broadside follows a letter from Republican Senator Tom Cotton to the US chipmaker's board chair this week expressing 'concern about the security and integrity of Intel's operations' and Tan's ties to China. Tan has been a prolific investor in Chinese tech companies, through his San Francisco-based venture capital firm as well as companies based in Hong Kong. His past investments have included Semiconductor Manufacturing International Corp, China's largest chip manufacturer. READ MORE Before being appointed Intel CEO earlier this year, Tan ran California-based Cadence Design Systems, which last week admitted to violating US export controls by selling its chip design tools to a Chinese university with close ties to the military. [ Intel warns senior Government figures that high energy costs could threaten Ireland's competitiveness Opens in new window ] Intel and the White House did not immediately respond to a request for comment on Trump's post. Intel shares dropped 3 per cent in pre-market trading in New York. Tan was appointed as Intel CEO in March after the Silicon Valley company's board ousted his predecessor Pat Gelsinger in December. Intel is the only US-headquartered company capable of producing advanced semiconductors, though it has so far largely missed out on the current boom for artificial intelligence chips. It has been awarded billions of dollars in US government subsidies and loans to support its chip manufacturing business, which has fallen far behind its rival Taiwan Semiconductor Manufacturing Company (TSMC). Intel has a major presence in Ireland, having established a presence here in 1989 with a manufacturing base in Leixlip, Co Kildare. According to its website, more than €30 billion has been invested in the Leixlip campus and 4,900 people work for Intel here. It also supports 115 suppliers here and accounted for 0.7 per cent of Irish GDP in 2023. The Irish operation has been downsized in recent years as part of cuts imposed globally. Some 195 mandatory redundancies are expected at Intel's Irish operations this autumn. However, amid a radical cost-cutting programme, Tan warned last month that Intel might be forced to abandon development of its next-generation manufacturing technology if it were unable to secure a 'significant external customer'. Such a move would hand a virtual monopoly of leading-edge chipmaking to TSMC. 'Intel is required to be a responsible steward of American taxpayer dollars and to comply with applicable security regulations,' Cotton wrote in Tuesday's letter to Intel's board chair, Frank Yeary. 'Mr Tan's associations raise questions about Intel's ability to fulfill these obligations.' - Copyright The Financial Times Limited 2025
